BANGKOK: The Thai Food and Drug Administration (FDA) has issued a public warning after laboratory tests found that a popular herbal inhaler failed to meet required safety standards,
The Straits Times reported.
Samples of the Hong Thai Herbal Inhaler, Formula 2, produced by Hong Thai Panich, were tested by the Department of Medical Sciences and found to contain excessive microbial contamination.
The tests showed high levels of aerobic bacteria, yeasts and moulds, as well as the presence of Clostridium species, which violate Thailand’s health regulations on product purity and safety.
Following the findings, the manufacturer has recalled Lot 000332, produced on Dec 9, 2024, and expiring on Dec 8, 2027, involving a total of 200,000 units.
The herbal inhaler, which was registered in 2021, has been widely sold across Thailand and neighbouring countries as a traditional remedy for nasal congestion and dizziness.
The FDA said the results were made public to protect consumers and ensure that only products meeting health standards remain on the market.
The agency also confirmed that legal action is being considered against the company for breaching product quality regulations.
